ATHENS, Ga., March 31 /PRNewswire/ -- ArunA Biomedical, Inc., a leader in human embryonic stem cell derived products, announced today that it has co-developed a validated kit to produce induced pluripotent stem cells with Open Biosystems now part of Thermo Fisher.
In the spirit of collaboration ArunA Biomedical and Open Biosystems will launch the complete and fully validated induced pluripotent stem cell (iPS) kits containing all the tools and reagents necessary to generate patient and disease specific cell lines for use in research applications in early April. The innovative viPS(TM) product offerings will include two kit formats and additional supplemental kits designed exclusively by the companies.
ArunA co-founder and CSO, Steven Stice said, "These kits are consistent with the scientific vision of our company. They exemplify ArunA's commitment to making stem cell research easier thereby enabling investigators the opportunity to make faster advances in the stem cell field. Induced pluripotent cells generated from these kits can help find cures for many genetic disorders ranging from certain types of Alzheimer's to Huntington's disease. "
The products will be marketed by Open Biosystems, now part of Thermo Fisher. For more information please visit the product website at: www.thermo.com/openbiosystems
About ArunA Biomedical
Located in Athens, Georgia, ArunA Biomedical, Inc. is a privately held biotechnology corporation dedicated to the discovery, manufacturing and commercialization of emerging new technologies in human stem cell research for use in drug discovery and basic research. ArunA is the first company to commercialize products derived from human embryonic stem cells and sees its proprietary technology as a catalyst leading to the discovery of novel therapeutic compounds, tests for neurotoxicity and breakthroughs in understanding human development and diseases. For more information, visit: www.arunabiomedical.com
This press release contains forward-looking statements regarding the company's potential impact on scientific research and collaborations with third parties. Certain conditions could alter the outcome or progress of these statements including but not limited to unexpected manufacturing issues, product performance and quality control/assurance issues. Forward- looking statements are based on the opinions, beliefs and expectations of the company or individuals quoted in the press release and the company does not assume any obligation to update these forward-looking statements if circumstances change.
|SOURCE ArunA Biomedical, Inc.|
Copyright©2009 PR Newswire.
All rights reserved